Fetal toxic effects and angiotensin-II-receptor antagonists [3]

Lancet

Volumn 358, Issue 9277, 2001, Pages 241-242

  Martinovic, Jelena ^b   Benachi, Alexandra ^b   Laurent, Nicole ^b   Daïkha Dahmane, Farida ^b   Gubler, Marie Claire ^a  

^a INSERM   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE; LABETALOL; LOSARTAN; METFORMIN; METHYLDOPA; NICARDIPINE; POTASSIUM CHLORIDE; RENIN; VALSARTAN;

ADULT; AMNIOINFUSION; AMNION FLUID; CASE REPORT; CELL COUNT; CONTROLLED STUDY; DRUG INDUCED DISEASE; ECHOGRAPHY; FEMALE; FETOTOXICITY; GESTATION PERIOD; HUMAN; HYPERTENSION; LETTER; NEPHRON; NON INSULIN DEPENDENT DIABETES MELLITUS; PREGNANCY TERMINATION; PRENATAL EXPOSURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BLOCKING; TERATOGENESIS; TREATMENT CONTRAINDICATION;

EID: 0035928388     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(01)05426-5     Document Type: Letter

References (5)

1. Losartan and fetal toxic effects
2. "Medullary ray glomerular counting" as a method of assessment of human nephrogenesis
3. Angiotensin-converting enzyme inhibitor fetopathy
4. Defining the susceptible period of developmental toxicity for the AT1-selective angiotensin II receptor antagonist losartan in rats
5. Teratogenic effects of ACE inhibitors and angiotensin II receptor antagonists